Apabetalone - Resverlogix

Drug Profile

Apabetalone - Resverlogix

Alternative Names: RVX-000222; RVX-208

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Resverlogix Corporation
  • Class Anti-inflammatories; Cardiovascular therapies; Quinazolines; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acute coronary syndromes; Atherosclerosis; Low HDL cholesterol
  • Phase II Prediabetic-state
  • Preclinical Renal failure
  • No development reported Alzheimer's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (PO, Capsule)
  • 24 Oct 2017 Hepalink USA enters into a Right of First Refusal Agreement with Resverlogix Corporation to develop, manufacture and commercialise pharmaceutical products containing apabetalone in USA
  • 26 Aug 2017 Updated efficacy data from the phase II trial in Atherosclerosis presented at the Annual Congress of the European Society of Cardiology (Aug-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top